Uji klinis Migrain di Texas
13 studi untuk Migrain mencari peserta di lokasi di Texas.
Kota di Texas
Teks studi resmi (Bahasa Inggris)
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- Alina Clinical Trials, LLC., Dallas
- North Texas Center for Clinical Research, Frisco
- DM Clinical Research - Cy Fair, Houston
- dan 6 lainnya
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05156398Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Dell Children's Medical Center, Austin
- Houston Clinical Trials, LLC, Bellaire
- FutureSearch Trials of Dallas, LLC, Dallas
- dan 5 lainnya
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04649242Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Dell Children's Medical Center, Austin
- Child Neurology Consultants of Austin - Central Austin, Austin
- Houston Clinical Trials, LLC, Bellaire
- dan 4 lainnya
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04743141A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- UT Health Austin at Dell Childrens Neurology Clinic /ID# 270577, Austin
- Earle Research /ID# 270424, Houston
- Clinpoint Trials /ID# 270261, Waxahachie
Menerima pesertaFase 3
Usia 12 hingga 17 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06810505Responding With Evidence and Access for Childhood Headaches
- Dell Children's Hospital-UT Health, Austin
Menerima peserta
Usia 10 hingga 17 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05889624Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- DHR Health Headache Center, McAllen
Menerima pesertaFase 4
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06972056Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- UT Health Austin at Dell Children's Neurology Clinic /ID# 244266, Austin
- Austin Regional Clinic - ARC Four Points /ID# 276301, Austin
- Velocity Clinical Research, Austin /ID# 230557, Austin
- dan 13 lainnya
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05125302Study of EVO756 in Adults With Migraine
- FutureSearch Trials of Neurology, Austin
- FutureSearch Trials of Dallas, Dallas
- SFF Medical Research Group LLC, Houston
Menerima pesertaFase 2
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07616128A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- FutureSearch Trials of Neurology, Austin
- Tekton Research, Austin
- APD Clinical Research, Cypress
- dan 7 lainnya
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT07645924A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
- Road Runner Research Ltd, San Antonio
Menerima pesertaFase 3
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 12 Jun 2026 · NCT05164172A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
- FutureSearch Trials, Austin
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT06602479Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?
- University Medical Center of El Paso, El Paso
Menerima pesertaFase awal 1
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06016465Stimulation of External Carotid Artery Circulation
- University of Texas Medical Branch, Galveston
Menerima peserta
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 20 Feb 2026 · NCT07402954Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.